277 related articles for article (PubMed ID: 31859241)
1. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
[TBL] [Abstract][Full Text] [Related]
2. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
[TBL] [Abstract][Full Text] [Related]
3. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
7. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
8. MCPIP1 Downregulation in Clear Cell Renal Cell Carcinoma Promotes Vascularization and Metastatic Progression.
Marona P; Górka J; Mazurek Z; Wilk W; Rys J; Majka M; Jura J; Miekus K
Cancer Res; 2017 Sep; 77(18):4905-4920. PubMed ID: 28716897
[TBL] [Abstract][Full Text] [Related]
9. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Serova M; Tijeras-Raballand A; Dos Santos C; Martinet M; Neuzillet C; Lopez A; Mitchell DC; Bryan BA; Gapihan G; Janin A; Bousquet G; Riveiro ME; Bieche I; Faivre S; Raymond E; de Gramont A
Oncotarget; 2016 Jun; 7(25):38467-86. PubMed ID: 27509260
[TBL] [Abstract][Full Text] [Related]
10. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Turajlic S; Xu H; Litchfield K; Rowan A; Horswell S; Chambers T; O'Brien T; Lopez JI; Watkins TBK; Nicol D; Stares M; Challacombe B; Hazell S; Chandra A; Mitchell TJ; Au L; Eichler-Jonsson C; Jabbar F; Soultati A; Chowdhury S; Rudman S; Lynch J; Fernando A; Stamp G; Nye E; Stewart A; Xing W; Smith JC; Escudero M; Huffman A; Matthews N; Elgar G; Phillimore B; Costa M; Begum S; Ward S; Salm M; Boeing S; Fisher R; Spain L; Navas C; Grönroos E; Hobor S; Sharma S; Aurangzeb I; Lall S; Polson A; Varia M; Horsfield C; Fotiadis N; Pickering L; Schwarz RF; Silva B; Herrero J; Luscombe NM; Jamal-Hanjani M; Rosenthal R; Birkbak NJ; Wilson GA; Pipek O; Ribli D; Krzystanek M; Csabai I; Szallasi Z; Gore M; McGranahan N; Van Loo P; Campbell P; Larkin J; Swanton C;
Cell; 2018 Apr; 173(3):595-610.e11. PubMed ID: 29656894
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy.
Ambrosetti D; Coutts M; Paoli C; Durand M; Borchiellini D; Montemagno C; Rastoin O; Borderie A; Grepin R; Rioux-Leclercq N; Bernhard JC; Pagès G; Dufies M
BJU Int; 2022 Jan; 129(1):80-92. PubMed ID: 34107167
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
13. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment.
Tamma R; Rutigliano M; Lucarelli G; Annese T; Ruggieri S; Cascardi E; Napoli A; Battaglia M; Ribatti D
Urol Oncol; 2019 Jun; 37(6):355.e11-355.e19. PubMed ID: 30738745
[TBL] [Abstract][Full Text] [Related]
14. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
15. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma.
Dall'Oglio MF; Ribeiro-Filho LA; Antunes AA; Crippa A; Nesrallah L; Gonçalves PD; Leite KR; Srougi M
J Urol; 2007 Aug; 178(2):425-8; discussion 428. PubMed ID: 17561167
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
17. Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.
Udayakumar D; Zhang Z; Xi Y; Dwivedi DK; Fulkerson M; Haldeman S; McKenzie T; Yousuf Q; Joyce A; Hajibeigi A; Notgrass H; de Leon AD; Yuan Q; Lewis MA; Madhuranthakam AJ; Sibley RC; Elias R; Guo J; Christie A; McKay RM; Cadeddu JA; Bagrodia A; Margulis V; Brugarolas J; Wang T; Kapur P; Pedrosa I
Clin Cancer Res; 2021 Sep; 27(17):4794-4806. PubMed ID: 34210685
[TBL] [Abstract][Full Text] [Related]
18. Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems.
Verine J; Colin D; Nheb M; Prapotnich D; Ploussard G; Cathelineau X; Desgrandchamps F; Mongiat-Artus P; Feugeas JP
Am J Surg Pathol; 2018 Apr; 42(4):423-441. PubMed ID: 29356723
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Tsuzuki T; Sassa N; Shimoyama Y; Morikawa T; Shiroki R; Kuroda M; Fukatsu A; Kuwahara K; Yoshino Y; Hattori R; Gotoh M
Histopathology; 2014 Mar; 64(4):484-93. PubMed ID: 24274732
[TBL] [Abstract][Full Text] [Related]
20. Complexity of tumor vasculature in clear cell renal cell carcinoma.
Qian CN; Huang D; Wondergem B; Teh BT
Cancer; 2009 May; 115(10 Suppl):2282-9. PubMed ID: 19402071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
